<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02663141</url>
  </required_header>
  <id_info>
    <org_study_id>9111257006</org_study_id>
    <nct_id>NCT02663141</nct_id>
  </id_info>
  <brief_title>Randomized Clinical Trial of Intravitreal Bevacizumab Versus Intravitreal Bevacizumab Combined With Losartan in the Treatment of Diabetic Macular Edema</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tehran University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Farabi Eye Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tehran University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine whether oral losartan is effective in the treatment of
      diabetic macular edema (DME) as an adjuvant for intravitreal bevacizumab (IVB).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>difference in ETDRS best-corrected visual acuity (BCVA) between arms</measure>
    <time_frame>Within 6 months from therapy</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference in frequency of intravitreal Bevacizumab injection between arms</measure>
    <time_frame>Within 6 months from therapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in central macular thickness(measured by spectral domain optical coherence tomography)</measure>
    <time_frame>Within 6 months from therapy</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>Losartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral losartan 50 mg daily for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral placebo daily for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan</intervention_name>
    <arm_group_label>Losartan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravitreal bevacizumab</intervention_name>
    <arm_group_label>Losartan</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All type 2 diabetes mellitus patients with clinically significant macular edema(CSME),
        except those mentioned as exclusion criteria

        Exclusion Criteria:

          1. Patients with Uncontrolled hypertension

          2. Patients with Proliferative diabetic retinopathy

          3. Patients Who received angiotensin converting enzyme inhibitor(ACEI) or angiotensin
             receptor blocker(ARB)

          4. Previous treatment for diabetic retinopathy (e.g., laser photocoagulation,
             photodynamic therapy, intravitreal injections of steroids, or anti-vascular
             endothelial growth factor, retinal surgery)

          5. media opacities

          6. evidence of any other ocular disease(e.g., glaucoma, uveitis, age related macular
             degeneration or etc.,)

          7. Pathologic myopia &gt; 6 Diopter

          8. Patients with poor fixation or cooperation

          9. Patients with renal or cardiac disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Farabi Eye Hospital</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 21, 2016</study_first_submitted>
  <study_first_submitted_qc>January 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2016</study_first_posted>
  <last_update_submitted>July 3, 2016</last_update_submitted>
  <last_update_submitted_qc>July 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Losartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

